1
Plasma haem can cause endothelial injury and organ dysfunction, and is normally scavenged by haemopexin to limit toxicity.
2
Future work will continue to optimize the bladder-sparing regimen while limiting toxicity.
3
The primary end point was safety, including the incidence of dose- limiting toxicities.
4
There were no dose limiting toxicities, therefore the MTD was not defined.
5
Overall, no dose- limiting toxicities or safety signals were observed in the study.
6
No dose- limiting toxicities were observed despite escalation to the highest dose level.
7
Dose- limiting toxicities were primarily enhanced epithelial reactions, but febrile neutropenia also occurred.
8
With the exception of chemical peritonitis-induced adhesions, no limiting toxicity was observed.
9
The main dose limiting toxicity was myelosuppression which seemed to be cumulative.
10
Dose- limiting toxicities were observed for one patient at the 400 mg dose.
11
No dose- limiting toxicities were identified, and maximum tolerated dose was not reached.
12
No dose- limiting toxicity was observed and the maximum-tolerated dose was not reached.
13
Thrombocytopenia was reported as a dose- limiting toxicity for both 254-S and carboplatin.
14
Dose- limiting toxicities were defined as grade 3 esophageal, cardiac, or pulmonary toxicity.
15
Results: All patients tolerated the single-fraction SBRT well without developing a dose- limiting toxicity.
16
No dose- limiting toxicities and treatment related severe adverse events were observed.